FDA Keeps Jazz’s SCLC Treatment on the Market Despite Failed Confirmatory Trial

The FDA has upheld the accelerated approval of Jazz Pharmaceuticals’ Zepzelca (lurbinectedin), even though the drug failed to reach its primary endpoint in the confirmatory Phase III ATLANTIS trial.